Active Ingredient History
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5). Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 3)
Acute Lung Injury (Phase 3)
Amyotrophic Lateral Sclerosis (Phase 3)
Atypical Hemolytic Uremic Syndrome (Phase 3)
Cardiopulmonary Bypass (Phase 3)
COVID-19 (Phase 4)
Dermatomyositis (Phase 2/Phase 3)
Genetic Diseases, Inborn (Phase 2)
Glomerulonephritis, IGA (Phase 2)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 3)
Hemoglobinuria, Paroxysmal (Phase 4)
Lupus Nephritis (Phase 2)
Myasthenia Gravis (Phase 3)
Neuromyelitis Optica (Phase 3)
Pneumonia, Viral (Phase 3)
Renal Insufficiency, Chronic (Phase 3)
Respiratory Distress Syndrome (Phase 3)
Thrombotic Microangiopathies (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
